Alios BioPharma Nets $41M to Develop Respiratory Therapies
April 09, 2014
Alios BioPharma, a biotechnology company developing therapeutics for respiratory viral diseases, has raised $41 million in Series B funding from all existing investors, including Novo Ventures, SR One, Roche Venture Fund and Novartis Ventures. Proceeds from the round will be used primarily to support continued clinical development of Alios' respiratory portfolio, including AL-8176, an anti-RSV nucleoside analog now in Phase 2 clinical development, and multiple late-stage preclinical development programs targeting influenza and rhinovirus. Alios previously raised $32 million of Series A funding in June 2009.
In the last two weeks, two additional companies that are focused on respiratory care have received venture funding: Vapotherm ($24 million) and Axikin Pharmaceuticals ($6 million).